moxifloxacin has been researched along with Endocarditis, Bacterial in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Giamarellou, H; Kyroudi, A; Papalois, A; Pefanis, A; Skiadas, I; Triantafyllidi, H; Tsaganos, T | 1 |
| Bock, M; Bruun, NE; Bundgaard, H; Christensen, JJ; Christiansen, U; Elming, H; Fosbøl, EL; Fuursted, K; Gill, S; Helweg-Larsen, J; Høfsten, D; Høiby, N; Ihlemann, N; Iversen, K; Kristensen, JH; Køber, L; Lemming, L; Lerche, CJ; Moser, C; Nielsen, HL; Pedersen, CT; Povlsen, JA; Pries-Heje, MM; Rosenvinge, FS; Schultz, M; Theut, AM; Tønder, N; van Hasselt, JGC; Wang, H | 1 |
| Drekonja, DM | 1 |
| Balla, J; Fehérvári, I; Kertész, A; Nemes, B; P Szabó, R; Szerafin, T; Zsom, L | 1 |
| Donta, I; Galani, L; Giamarellou, H; Iliopoulos, D; Karayiannakos, P; Pefanis, A; Sakka, V; Skiadas, I; Triantafyllidi, H | 1 |
| Hartmann, B; Keller, F; Maus, S; Rothermund, L | 1 |
| Amann, K; Bröcker, EB; Müller, PA; Trautmann, A | 1 |
| Georgopoulos, A; Graninger, W; Grisold, AJ; Hirschl, AM; Presterl, E; Reichmann, S | 1 |
| Athanasopoulos, G; Donta, I; Galani, L; Giamarellou, H; Iliopoulos, D; Pefanis, A; Sakka, V | 1 |
| Bachinskaia, EN; Beloborodova, NV; Popov, DA; Sedrakian, AR; Vostrikova, TIu | 1 |
| Bilgen, FS; Kut, MS; Palaz, FK; Sanioğlu, S; Sokullu, O; Yavuz, SS | 1 |
| Berrington, AW; Gould, FK; Perry, JD | 1 |
| Bain, HH; Berrington, AW; Gould, FK; Koerner, RJ; Perry, JD | 1 |
| Entenza, JM; Glauser, MP; Moreillon, P; Que, YA; Vouillamoz, J | 1 |
14 other study(ies) available for moxifloxacin and Endocarditis, Bacterial
| Article | Year |
|---|---|
Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.
Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Aortic Valve; Aza Compounds; Dexamethasone; Disease Models, Animal; Echocardiography; Endocarditis, Bacterial; Fluoroquinolones; Humans; Methicillin; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome | 2007 |
Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy.
Topics: Amoxicillin; Anti-Bacterial Agents; Dicloxacillin; Endocarditis; Endocarditis, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Rifampin | 2023 |
Erysipelothrix bacteremia without endocarditis: rare event or under-reported occurrence?
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteremia; Echocardiography, Transesophageal; Endocarditis, Bacterial; Endocardium; Erysipelothrix; Erysipelothrix Infections; Fluoroquinolones; Hand; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Treatment Outcome | 2013 |
[Infective endocarditis caused by Chlamydia pneumoniae after liver transplantation. Case report].
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Aortic Valve; Aphasia; Brain; Calcineurin; Ceftriaxone; Chlamydia; Coronary Artery Bypass; Drug Administration Schedule; Echocardiography, Transesophageal; Endocarditis, Bacterial; Female; Fluoroquinolones; Gentamicins; Heart Valve Prosthesis Implantation; Humans; Intracranial Embolism; Liver Transplantation; Magnetic Resonance Imaging; Middle Aged; Moxifloxacin; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2015 |
Successful treatment with moxifloxacin of experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Animals; Anti-Bacterial Agents; Aortic Valve; Aza Compounds; Disease Models, Animal; Endocarditis, Bacterial; Female; Fluoroquinolones; Heart Valve Diseases; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rabbits; Staphylococcal Infections; Treatment Outcome; Vancomycin | 2009 |
Thrombocytopenia, INR prolongation and fall in fibrinogen under daptomycin.
Topics: Anti-Bacterial Agents; Aza Compounds; Daptomycin; Endocarditis, Bacterial; Fibrinogen; Fluoroquinolones; Humans; International Normalized Ratio; Male; Middle Aged; Moxifloxacin; Quinolines; Renal Dialysis; Staphylococcal Infections; Staphylococcus epidermidis; Thrombocytopenia; Vancomycin | 2011 |
[Maculo-papular exanthem with acute renal failure. Drug-induced hypersensitivity syndrome].
Topics: Acute Kidney Injury; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aortic Valve; Aza Compounds; Biopsy; Diagnosis, Differential; Drug Eruptions; Drug Therapy, Combination; Endocarditis, Bacterial; Eosinophilia; Fluoroquinolones; Glucocorticoids; Humans; Kidney; Legionnaires' Disease; Male; Meropenem; Moxifloxacin; Nephritis, Interstitial; Quinolines; Sepsis; Skin; Thienamycins; Vancomycin | 2012 |
Viridans streptococci in endocarditis and neutropenic sepsis: biofilm formation and effects of antibiotics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Bacteremia; Biofilms; Blood; Culture Media; Endocarditis, Bacterial; Female; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Neutropenia; Penicillins; Quinolines; Streptococcal Infections; Teicoplanin; Viridans Streptococci | 2005 |
Successful moxifloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aortic Valve; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Endocarditis, Bacterial; Female; Fluoroquinolones; Heart Valve Diseases; Moxifloxacin; Quinolines; Rabbits; Streptococcal Infections; Streptococcus oralis | 2005 |
[Moxifloxacin clinical and microbiological efficacy in therapy of infectious endocarditis].
Topics: Adult; Anti-Infective Agents; Aza Compounds; Cardiac Surgical Procedures; Endocarditis, Bacterial; Female; Fluoroquinolones; Humans; Male; Medical Records; Middle Aged; Moxifloxacin; Quinolines; Retrospective Studies; Treatment Outcome | 2006 |
Stenotrophomonas maltophilia endocarditis treated with moxifloxacin-ceftazidime combination and annular wrapping technique.
Topics: Adult; Anti-Bacterial Agents; Aortic Valve; Aza Compounds; Ceftazidime; Drug Therapy, Combination; Endocarditis, Bacterial; Equipment Design; Fluoroquinolones; Gram-Negative Bacterial Infections; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Humans; Male; Moxifloxacin; Quinolines; Stenotrophomonas maltophilia | 2008 |
Bactericidal activity of moxifloxacin against Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Endocarditis, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus | 2001 |
Treatment of Staphylococcus aureus endocarditis using moxifloxacin.
Topics: Adult; Anti-Infective Agents; Aza Compounds; Endocarditis, Bacterial; Fluoroquinolones; Humans; Male; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus | 2001 |
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; Drug Resistance, Microbial; Endocarditis, Bacterial; Fluoroquinolones; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rats; Spleen; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2001 |